Skip to main content
Breast Cancer Research : BCR logoLink to Breast Cancer Research : BCR
. 2024 May 24;26:83. doi: 10.1186/s13058-024-01833-6

Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

Samuel A Jacobs 1,, Ying Wang 1, Jame Abraham 1,2, Huichen Feng 1, Alberto J Montero 1,2,3, Corey Lipchik 1, Melanie Finnigan 1, Rachel C Jankowitz 1,4,5, Mohamad A Salkeni 1,6,7, Sai K Maley 1, Shannon L Puhalla 1,8,9, Fanny Piette 10, Katie Quinn 11, Kyle Chang 11, Rebecca J Nagy 11, Carmen J Allegra 1,12, Kelly Vehec 1, Norman Wolmark 1,8, Peter C Lucas 1,8,9,13, Ashok Srinivasan 1,14, Katherine L Pogue-Geile 1
PMCID: PMC11127282  PMID: 38790033

Correction: Jacobs et al. Breast Cancer Research (2024) 26:69.

10.1186/s13058-024-01823-8.

Following the publication of the original article, there were several errors, as follows:

In the abstract, Results section, “95% CI” should be included in the sixth sentence. It should read: “Molecular Response scores were significantly associated with both PFS (HR 0.28, 95% CI 0.09-0.90, P = 0.033) and best response (P = 0.037).”

On page 4, left-hand column: The word “samples,” after the word “two,” was mistakenly removed during typesetting. The correct statement should have been “ … the percent ctDNA change between the two timepoints based on the mean variant allele frequency (VAF) between two samples (mean VAF2/mean VAF1) -1 ? 100%.”

On page 7, left-hand column, a statement of “0.09-0.90, P = 0.033 using Wilcox test” was duplicated and has been removed.

The original article has been corrected.

Footnotes

The online version of the original article can be found at 10.1186/s13058-024-01823-8.

Publisher‘s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Articles from Breast Cancer Research : BCR are provided here courtesy of BMC

RESOURCES